News

Get the latest on BIO's announcements, positions and views on everything from healthcare to biofuels. 

Press Releases
BIO Applauds Introduction of Bipartisan Bill to…
Legislation will help spur the development of lifesaving treatments and cures WASHINGTON D.C. (February 25, 2025) – John Crowley, president and CEO of the Biotechnology Innovation Organization (BIO), released the following statement…
BIO Applauds Introduction of Bipartisan ORPHAN…
Urges Congress to support rare disease patients & support the billWASHINGTON, D.C. (February 5, 2025) – John F. Crowley, President & CEO of the Biotechnology Innovation Organization (BIO), today released the following statement after…
BIO Statement on New List of Medicines Targeted…
WASHINGTON, D.C. (January 17, 2025) – The Biotechnology Innovation Organization (BIO) today released the following statement after the Biden administration released a list of 15 medicines being selected for government price setting:“In the final…
Letters, Testimony, & Comments
BIO Letter to Congressional Leadership on the…
One thing that we can all agree on is the need to give our children a fighting chance so they can lead long and productive lives. That is why it is critical to pass the bipartisan Give Kids a Chance Act and ensure the Pediatric Priority Review…
John’s One-Year Anniversary Letter to BIO…
Dear Colleagues, This month marks my one-year anniversary as BIO's CEO. Like most of us in biotech, this post has been a labor of love. At no time in my 25-year career in this industry have I ever witnessed such awe-inspiring science. Today, we…
BIO Comments on Office of Management and Budget …
Re: BIO Comments on Office of Management and Budget (OMB) Statistical Policy Directive No. 8 North American Industry Classification System (NAICS)-Request for Comments on Possible Revisions for 2027 (USBC–2024–0032)Dear Ms. Orvis,The Biotechnology…
Amicus Briefs
BIO Files Amicus Brief in California Supreme…
BIO filed an amicus brief in the Supreme Court of the State of California, encouraging its review of the lower court decision in the Gilead Tenofovir Cases.The Court of Appeal decision operates from a misunderstanding of the drug development and FDA…
BIO files Amicus Brief in Colorado PDAB Case
The Biotechnology Innovation Organization (“BIO”) respectfully moves the Court for leave to file an amicus brief in support of Plaintiffs’ response in opposition to the Defendants’ cross-motion for summary judgment. Copies of the proposed brief and…
BIO Files Amicus Brief in Continuing Effort to…
BIO filed an amicus brief in a continuing effort to challenge courts' decisions that undermine FDA authority and hinder patient access to medications.The brief was filed in the Supreme Court of the United States (SCOTUS), following the August 2023…